MFST News 12/26/2016 - 0.003
Post# of 273249
Posted On: 12/26/2016 6:26:02 AM
Medifirst Solutions Inc. $MFST News
Last updated 12/26/2016 - 0.003
Medifirst Solutions Appoints Bill White to Its Advisory Board
Nov 22, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Appoints Bill White to Its Advisory Board
FREEHOLD, NJ--(Marketwired - Nov 22, 2016) - Medifirst Solutions, Inc. (OTCQB: MFST) (the "Company" or "Medifirst"
, a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce the appointment of Bill White to its Advisory Board. Mr. White will serve as a senior advisor to CEO Bruce J. Schoengood.
Bill White is Chief Financial Officer, Treasurer and Board Secretary of Intellicheck Mobilisa, a leading software technology company providing wireless technology and identity systems for various applications including mobile and handheld, access control and security systems for the commercial, government and military markets. Bill White has more than 28 years of experience in financial management, operations and business development. In addition to his experience as an officer of Intellicheck Mobilisa, he served 11 years as the Chief Financial Officer, Secretary and Treasurer of FocusMicro, Inc. (FM). As co-founder of FM, Mr. White played an integral role in growing the business from the company's inception to over $36 Million in annual revenue in a five-year period. Mr. White has broad domestic and international experience including managing rapid and significant growth, import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic planning, resource allocation, tax compliance and organization development. Prior to co-founding FM, he served 15 years in various financial leadership positions in the government sector.
Mr. White stated, "I'm very excited and pleased to join the Medifirst Solutions Advisory Board. The laser sector within the healthcare industry is booming and The Time Machine Lasers present a unique product with explosive growth potential. I look forward to assisting the company in monetizing its incredible technology." Stated CEO Bruce J. Schoengood, "Bill is a key addition to our team. He brings decades of management experience that will be invaluable to Medifirst as it now enters its sales, marketing and distribution phase. We are honored and excited to have him join our Board as a senior advisor."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc.
Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS APPOINTS BILL WHITE TO ITS ADVISORY BOARD
Nov 22, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – November 22, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) A provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device is pleased to announce the appointment of Bill White to its Advisory Board. Mr. White will serve as a senior advisor to CEO Bruce J. Schoengood.
Bill White is Chief Financial Officer, Treasurer and Board Secretary of Intellicheck Mobilisa, a leading software technology company providing wireless technology and identity systems for various applications including mobile and handheld, access control and security systems for the commercial, government and military markets. Bill White has more than 28 years of experience in financial management, operations and business development. In addition to his experience as an officer of Intellicheck Mobilisa, he served 11 years as the Chief Financial Officer, Secretary and Treasurer of FocusMicro, Inc. (FM). As co-founder of FM, Mr. White played an integral role in growing the business from the company's inception to over $36 Million in annual revenue in a five year period. Mr. White has broad domestic and international experience including managing rapid and significant growth, import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic planning, resource allocation, tax compliance and organization development. Prior to co-founding FM, he served 15 years in various financial leadership positions in the government sector.
Mr. White stated, “I'm very excited and pleased to join the Medifirst Solutions Advisory Board. The laser sector within the healthcare industry is booming and The Time Machine Lasers present a unique product with explosive growth potential. I look forward to assisting the company in monetizing its incredible technology.” Stated CEO Bruce J. Schoengood, “Bill is a key addition to our team. He brings decades of management experience that will be invaluable to Medifirst as it now enters its sales, marketing and distribution phase. We are honored and excited to have him join our Board as a senior advisor.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Update on International Sales
Nov 21, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Update on International Sales
FREEHOLD, NJ--(Marketwired - Nov 21, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst", a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device would like to update its shareholders on its progress in the international market. The Company has previously announced that it has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Medifirst is pleased to announce that it has been asked to bring its medical staff to Morocco and Dubai to demonstrate its laser technology as part of finalizing its first international sales orders. The Company is optimistic that it will have firm commitments for bulk orders once the demonstrations are completed.
Commented CEO Bruce J. Schoengood, "We are thrilled with the response to our lasers by the international community and we are excited to complete the demonstrations, meet our new vendors, complete and fulfill our purchase orders and finalize our new distribution agreements. We are eager to have our Medical Director and staff show how effective our lasers are in reducing pain." The Company has scheduled the demonstrations in January and anticipates that it will, as previously announced, begin booking sales in Q1 2017. Continued Schoengood, "As we continue to set up international operations, we will also be training licensed technicians to use the laser so as to expedite sales in the Mid-East, Spain and Africa."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc.
Investor Relations
(732) 786-8044
admin@medifirstsolutions.com
www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES UPDATE ON INTERNATIONAL SALES
Nov 21, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – November 21, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) A provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device would like to update its shareholders on its progress in the international market. The Company has previously announced that it has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Medifirst is pleased to announce that it has been asked to bring it medical staff to Morocco and Dubai to demonstrate its laser technology as part of finalizing its first international sales orders. The Company is optimistic that it will have firm commitments for bulk orders once the demonstrations are completed. Commented CEO Bruce J. Schoengood, “We are thrilled with the response to our lasers by the international community and we are excited to complete the demonstrations, meet our new vendors, complete and fulfill our purchase orders and finalize our new distribution agreements. We are eager to have our Medical Director and staff show how effective our lasers are in reducing pain.” The Company has scheduled the demonstrations in January and anticipates that it will, as previously announced, begin booking sales in Q1 2017. Continued Schoengood, “As we continue to set up international operations, we will also be training licensed technicians to use the laser so as to expedite sales in the Mid-East, Spain and Africa.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Update Regarding International Sales and Operations
Nov 03, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Update Regarding International Sales and Operations
FREEHOLD, NJ--(Marketwired - Nov 3, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst" would like to update shareholders regarding recent company developments for international sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst recently announced that it has hired a Sales Director to set up operations for sales in international markets. We are pleased to announce that Medifirst has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Providing pain relief to patients to reduce reliance on prescription medications is a top priority for these buyers and all representatives expressed very strong interest in acquiring The Time Machine Laser for their hospitals and clinics. Currently, Medifirst is setting up demonstrations and providing due diligence regarding the laser certifications, protocols and treatments. Additionally, the Company is pleased to announce that it has completed setting up its FDA mandated internal controls and compliance procedures that are required before initiating sales. Commented President Bruce J. Schoengood, "We are on track to initiating sales, and we are very excited at the opportunity to provide our Time Machine Laser to the international markets. Providing an alternative treatment for pain related ailments can provide substantial saving to the healthcare providers who absorb the cost of expensive pain medications for patients who have to live everyday in pain." The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc.
Investor Relations
(732) 786-8044
admin@medifirstsolutions.com
www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES UPDATE REGARDING INTERNATIONAL SALES AND OPERATIONS
Nov 03, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – November 3, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) would like to update shareholders regarding recent company developments for international sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst recently announced that it has hired a Sales Director to set up operations for sales in international markets. We are pleased to announce that Medifirst has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Providing pain relief to patients to reduce reliance on prescription medications is a top priority for these buyers and all representatives expressed very strong interest in acquiring The Time Machine Laser for their hospitals and clinics. Currently, Medifirst is setting up demonstrations and providing due diligence regarding the laser certifications, protocols and treatments. Additionally, the Company is pleased to announce that it has completed setting up its FDA mandated internal controls and compliance procedures that are required before initiating sales. Commented President Bruce J. Schoengood, “We are on track to initiating sales, and we are very excited at the opportunity to provide our Time Machine Laser to the international markets. Providing an alternative treatment for pain related ailments can provide substantial saving to the healthcare providers who absorb the cost of expensive pain medications for patients who have to live everyday in pain.” The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Update Regarding Sales and Operations
Oct 17, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Update Regarding Sales and Operations
FREEHOLD, NJ--(Marketwired - Oct 17, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst" would like to update shareholders regarding recent company developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it anticipates completing its FDA mandated internal controls and compliance procedures within the next 30 days. Additionally, the Company has completed setting up its sales and training operation in its new location in Marlboro, New Jersey and has begun to hire a sales force to initiate sales and set up events to introduce the Time Machine Laser to healthcare professionals. Commented President Bruce J. Schoengood, "We are excited to be initiating sales, which we expect to begin Q1 2017 and the company is now fast-tracked to completing all internal compliance, setting up sales infrastructure and purchasing additional inventory and accessories to initiate sales." Fifty additional laser units, with an anticipated wholesale value of approximately $500,000, have been ordered for the initial sales roll-out. In addition, custom cases have been designed and ordered. Regarding international sales, Medifirst is pleased to announce that it currently has a Sales Director setting up sales operations and territories including compliance in Dubai, various Mid-East countries, Morocco, Spain and Africa. Commented CEO Schoengood, "The initial reaction to our Laser in the International Market has been extremely positive and we are committed to providing the resources and personnel necessary to build an international brand. Our price point and manufacturing cost will allow us to be very competitive in the global marketplace." The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact:
Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES UPDATE REGARDING SALES AND OPERATIONS
Oct 17, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – October 17, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) would like to update shareholders regarding recent company developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it anticipates completing its FDA mandated internal controls and compliance procedures within the next 30 days. Additionally, the Company has completed setting up its sales and training operation in its new location in Marlboro, New Jersey and has begun to hire a sales force to initiate sales and set up events to introduce the Time Machine Laser to healthcare professionals. Commented President Bruce J. Schoengood, “We are excited to be initiating sales, which we expect to begin Q1 2017 and the company is now fast-tracked to completing all internal compliance, setting up sales infrastructure and purchasing additional inventory and accessories to initiate sales.” Fifty additional laser units, with an anticipated wholesale value of approximately $500,000, have been ordered for the initial sales roll-out. In addition, custom cases have been designed and ordered. Regarding international sales, Medifirst is pleased to announce that it currently has a Sales Director setting up sales operations and territories including compliance in Dubai, various Mid-East countries, Morocco, Spain and Africa. Commented CEO Schoengood, “The initial reaction to our Laser in the International Market has been extremely positive and we are committed to providing the resources and personnel necessary to build an international brand. Our price point and manufacturing cost will allow us to be very competitive in the global marketplace.” The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Shareholder Update
Sep 13, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Shareholder Update
Medifirst Continues to Ramp Up for Sales
FREEHOLD, NJ--(Marketwired - Sep 13, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst" would like to update shareholders regarding recent company developments. As previously announced, Medifirst Solutions, Inc., received 510(k) clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it has made substantial progress in setting up its infrastructure for sales and compliance. The Company has engaged MDI Consultants, a leading provider of quality assurance, regulatory compliance, FDA consulting and clinical services to the healthcare industry. MDI Consultants will be hands-on with assisting and overseeing the implementation of the Company's internal controls and procedures as mandated by the FDA. These controls and procedures will be implemented in the Company's sales office, as well as at its manufacturer's facility. Commented President Bruce J. Schoengood, "We are very pleased to continue our relationship with MDI Consultants, who played a crucial role in successfully getting the FDA clearance, as Medifirst enters into the sales phase of operations."
In preparing to ramp up and roll out its sales division, Medifirst is pleased to announce that it has leased new office space in which to run its sales and training functions and operations which will include all FDA mandated internal controls and procedures. Medifirst's new office space, located in Marlboro, New Jersey, will provide professional space for training and testing. It will also handle all administrative functions for the Laser Division.
The Company previously announced that it was aggressively putting together a sales & distribution team to offer its Time Machine Lasers in the US market. Continued CEO Schoengood, "We have come to terms with an experienced National Sales Director with established credentials in the medical device industry and upon the completion of contracts and agreements, the Company will release an official announcement which is anticipated in the upcoming days. Additionally, the company has come to terms with additional top industry advisors and announcements are forthcoming as agreements are completed."
Continued CEO Schoengood, "Medifirst has also made substantial progress for financing, inventory and manufacturing, as well as marketing and advertising. All components of building a national brand with national sales are being addressed. We will be releasing updates on these developments in the upcoming days and weeks. The Company appreciates the patience of its shareholders and supporters during this exciting time."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc
Investor Relations
(732) 786-8044
admin@medifirstsolutions.com
www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES SHAREHOLDER UPDATE
Sep 13, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: info@medifirstsolutions.com
Website: www.medifirstsolutions.com
Medifirst continues to ramp up for sales
Freehold, NJ – September 13, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) would like to update shareholders regarding recent company developments. As previously announced, Medifirst Solutions, Inc., received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it has made substantial progress in setting up its infrastructure for sales and compliance. The Company has engaged MDI Consultants, a leading provider of quality assurance, regulatory compliance, FDA consulting and clinical services to the healthcare industry. MDI Consultants will be hands-on with assisting and overseeing the implementation of the Company’s internal controls and procedures as mandated by the FDA. These controls and procedures will be implemented in the Company’s sales office, as well as at its manufacturer’s facility. Commented President Bruce J. Schoengood, “We are very pleased to continue our relationship with MDI Consultants, who played a crucial role in successfully getting the FDA clearance, as Medifirst enters into the sales phase of operations.”
In preparing to ramp up and roll out its sales division, Medifirst is pleased to announce that it has leased new office space in which to run its sales and training functions and operations which will include all FDA mandated internal controls and procedures. Medifirst’s new office space, located in Marlboro, New Jersey, will provide professional space for training and testing. It will also handle all administrative functions for the Laser Division.
The Company previously announced that it was aggressively putting together a sales & distribution team to offer its Time Machine Lasers in the US market. Continued CEO Schoengood, “We have come to terms with an experienced National Sales Director with established credentials in the medical device industry and upon the completion of contracts and agreements, the Company will release an official announcement which is anticipated in the upcoming days. Additionally, the company has come to terms with additional top industry advisors and announcements are forthcoming as agreements are completed.”
Continued CEO Schoengood, “Medifirst has also made substantial progress for financing, inventory and manufacturing, as well as marketing and advertising. All components of building a national brand with national sales are being addressed. We will be releasing updates on these developments in the upcoming days and weeks. The Company appreciates the patience of its shareholders and supporters during this exciting time.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Last updated 12/26/2016 - 0.003
Medifirst Solutions Appoints Bill White to Its Advisory Board
Nov 22, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Appoints Bill White to Its Advisory Board
FREEHOLD, NJ--(Marketwired - Nov 22, 2016) - Medifirst Solutions, Inc. (OTCQB: MFST) (the "Company" or "Medifirst"
, a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce the appointment of Bill White to its Advisory Board. Mr. White will serve as a senior advisor to CEO Bruce J. Schoengood. Bill White is Chief Financial Officer, Treasurer and Board Secretary of Intellicheck Mobilisa, a leading software technology company providing wireless technology and identity systems for various applications including mobile and handheld, access control and security systems for the commercial, government and military markets. Bill White has more than 28 years of experience in financial management, operations and business development. In addition to his experience as an officer of Intellicheck Mobilisa, he served 11 years as the Chief Financial Officer, Secretary and Treasurer of FocusMicro, Inc. (FM). As co-founder of FM, Mr. White played an integral role in growing the business from the company's inception to over $36 Million in annual revenue in a five-year period. Mr. White has broad domestic and international experience including managing rapid and significant growth, import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic planning, resource allocation, tax compliance and organization development. Prior to co-founding FM, he served 15 years in various financial leadership positions in the government sector.
Mr. White stated, "I'm very excited and pleased to join the Medifirst Solutions Advisory Board. The laser sector within the healthcare industry is booming and The Time Machine Lasers present a unique product with explosive growth potential. I look forward to assisting the company in monetizing its incredible technology." Stated CEO Bruce J. Schoengood, "Bill is a key addition to our team. He brings decades of management experience that will be invaluable to Medifirst as it now enters its sales, marketing and distribution phase. We are honored and excited to have him join our Board as a senior advisor."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA"
to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc.
Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS APPOINTS BILL WHITE TO ITS ADVISORY BOARD
Nov 22, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – November 22, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) A provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device is pleased to announce the appointment of Bill White to its Advisory Board. Mr. White will serve as a senior advisor to CEO Bruce J. Schoengood.
Bill White is Chief Financial Officer, Treasurer and Board Secretary of Intellicheck Mobilisa, a leading software technology company providing wireless technology and identity systems for various applications including mobile and handheld, access control and security systems for the commercial, government and military markets. Bill White has more than 28 years of experience in financial management, operations and business development. In addition to his experience as an officer of Intellicheck Mobilisa, he served 11 years as the Chief Financial Officer, Secretary and Treasurer of FocusMicro, Inc. (FM). As co-founder of FM, Mr. White played an integral role in growing the business from the company's inception to over $36 Million in annual revenue in a five year period. Mr. White has broad domestic and international experience including managing rapid and significant growth, import/export, implementing tough cost management initiatives, exploiting new growth opportunities, merger and acquisitions, strategic planning, resource allocation, tax compliance and organization development. Prior to co-founding FM, he served 15 years in various financial leadership positions in the government sector.
Mr. White stated, “I'm very excited and pleased to join the Medifirst Solutions Advisory Board. The laser sector within the healthcare industry is booming and The Time Machine Lasers present a unique product with explosive growth potential. I look forward to assisting the company in monetizing its incredible technology.” Stated CEO Bruce J. Schoengood, “Bill is a key addition to our team. He brings decades of management experience that will be invaluable to Medifirst as it now enters its sales, marketing and distribution phase. We are honored and excited to have him join our Board as a senior advisor.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Update on International Sales
Nov 21, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Update on International Sales
FREEHOLD, NJ--(Marketwired - Nov 21, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst"
, a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device would like to update its shareholders on its progress in the international market. The Company has previously announced that it has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Medifirst is pleased to announce that it has been asked to bring its medical staff to Morocco and Dubai to demonstrate its laser technology as part of finalizing its first international sales orders. The Company is optimistic that it will have firm commitments for bulk orders once the demonstrations are completed. Commented CEO Bruce J. Schoengood, "We are thrilled with the response to our lasers by the international community and we are excited to complete the demonstrations, meet our new vendors, complete and fulfill our purchase orders and finalize our new distribution agreements. We are eager to have our Medical Director and staff show how effective our lasers are in reducing pain." The Company has scheduled the demonstrations in January and anticipates that it will, as previously announced, begin booking sales in Q1 2017. Continued Schoengood, "As we continue to set up international operations, we will also be training licensed technicians to use the laser so as to expedite sales in the Mid-East, Spain and Africa."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA"
to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc.
Investor Relations
(732) 786-8044
admin@medifirstsolutions.com
www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES UPDATE ON INTERNATIONAL SALES
Nov 21, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – November 21, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) A provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device would like to update its shareholders on its progress in the international market. The Company has previously announced that it has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Medifirst is pleased to announce that it has been asked to bring it medical staff to Morocco and Dubai to demonstrate its laser technology as part of finalizing its first international sales orders. The Company is optimistic that it will have firm commitments for bulk orders once the demonstrations are completed. Commented CEO Bruce J. Schoengood, “We are thrilled with the response to our lasers by the international community and we are excited to complete the demonstrations, meet our new vendors, complete and fulfill our purchase orders and finalize our new distribution agreements. We are eager to have our Medical Director and staff show how effective our lasers are in reducing pain.” The Company has scheduled the demonstrations in January and anticipates that it will, as previously announced, begin booking sales in Q1 2017. Continued Schoengood, “As we continue to set up international operations, we will also be training licensed technicians to use the laser so as to expedite sales in the Mid-East, Spain and Africa.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Update Regarding International Sales and Operations
Nov 03, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Update Regarding International Sales and Operations
FREEHOLD, NJ--(Marketwired - Nov 3, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst"
would like to update shareholders regarding recent company developments for international sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Medifirst recently announced that it has hired a Sales Director to set up operations for sales in international markets. We are pleased to announce that Medifirst has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Providing pain relief to patients to reduce reliance on prescription medications is a top priority for these buyers and all representatives expressed very strong interest in acquiring The Time Machine Laser for their hospitals and clinics. Currently, Medifirst is setting up demonstrations and providing due diligence regarding the laser certifications, protocols and treatments. Additionally, the Company is pleased to announce that it has completed setting up its FDA mandated internal controls and compliance procedures that are required before initiating sales. Commented President Bruce J. Schoengood, "We are on track to initiating sales, and we are very excited at the opportunity to provide our Time Machine Laser to the international markets. Providing an alternative treatment for pain related ailments can provide substantial saving to the healthcare providers who absorb the cost of expensive pain medications for patients who have to live everyday in pain." The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA"
to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc.
Investor Relations
(732) 786-8044
admin@medifirstsolutions.com
www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES UPDATE REGARDING INTERNATIONAL SALES AND OPERATIONS
Nov 03, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – November 3, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) would like to update shareholders regarding recent company developments for international sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst recently announced that it has hired a Sales Director to set up operations for sales in international markets. We are pleased to announce that Medifirst has met with medical representatives and buyers in Dubai, Saudi Arabia, Kuwait, Qatar, Morocco and Spain. Providing pain relief to patients to reduce reliance on prescription medications is a top priority for these buyers and all representatives expressed very strong interest in acquiring The Time Machine Laser for their hospitals and clinics. Currently, Medifirst is setting up demonstrations and providing due diligence regarding the laser certifications, protocols and treatments. Additionally, the Company is pleased to announce that it has completed setting up its FDA mandated internal controls and compliance procedures that are required before initiating sales. Commented President Bruce J. Schoengood, “We are on track to initiating sales, and we are very excited at the opportunity to provide our Time Machine Laser to the international markets. Providing an alternative treatment for pain related ailments can provide substantial saving to the healthcare providers who absorb the cost of expensive pain medications for patients who have to live everyday in pain.” The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Update Regarding Sales and Operations
Oct 17, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Update Regarding Sales and Operations
FREEHOLD, NJ--(Marketwired - Oct 17, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst"
would like to update shareholders regarding recent company developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Medifirst is pleased to announce that it anticipates completing its FDA mandated internal controls and compliance procedures within the next 30 days. Additionally, the Company has completed setting up its sales and training operation in its new location in Marlboro, New Jersey and has begun to hire a sales force to initiate sales and set up events to introduce the Time Machine Laser to healthcare professionals. Commented President Bruce J. Schoengood, "We are excited to be initiating sales, which we expect to begin Q1 2017 and the company is now fast-tracked to completing all internal compliance, setting up sales infrastructure and purchasing additional inventory and accessories to initiate sales." Fifty additional laser units, with an anticipated wholesale value of approximately $500,000, have been ordered for the initial sales roll-out. In addition, custom cases have been designed and ordered. Regarding international sales, Medifirst is pleased to announce that it currently has a Sales Director setting up sales operations and territories including compliance in Dubai, various Mid-East countries, Morocco, Spain and Africa. Commented CEO Schoengood, "The initial reaction to our Laser in the International Market has been extremely positive and we are committed to providing the resources and personnel necessary to build an international brand. Our price point and manufacturing cost will allow us to be very competitive in the global marketplace." The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA"
to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pinpoint accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact:
Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES UPDATE REGARDING SALES AND OPERATIONS
Oct 17, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: admin@medifirstsolutions.com
Website: www.medifirstsolutions.com
Freehold, NJ – October 17, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) would like to update shareholders regarding recent company developments regarding its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it anticipates completing its FDA mandated internal controls and compliance procedures within the next 30 days. Additionally, the Company has completed setting up its sales and training operation in its new location in Marlboro, New Jersey and has begun to hire a sales force to initiate sales and set up events to introduce the Time Machine Laser to healthcare professionals. Commented President Bruce J. Schoengood, “We are excited to be initiating sales, which we expect to begin Q1 2017 and the company is now fast-tracked to completing all internal compliance, setting up sales infrastructure and purchasing additional inventory and accessories to initiate sales.” Fifty additional laser units, with an anticipated wholesale value of approximately $500,000, have been ordered for the initial sales roll-out. In addition, custom cases have been designed and ordered. Regarding international sales, Medifirst is pleased to announce that it currently has a Sales Director setting up sales operations and territories including compliance in Dubai, various Mid-East countries, Morocco, Spain and Africa. Commented CEO Schoengood, “The initial reaction to our Laser in the International Market has been extremely positive and we are committed to providing the resources and personnel necessary to build an international brand. Our price point and manufacturing cost will allow us to be very competitive in the global marketplace.” The Company appreciates the patience of its shareholders and supporters during this exciting time and will continue to provide updates in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Medifirst Solutions Announces Shareholder Update
Sep 13, 2016
OTC Disclosure & News Service
-
Medifirst Solutions Announces Shareholder Update
Medifirst Continues to Ramp Up for Sales
FREEHOLD, NJ--(Marketwired - Sep 13, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst"
would like to update shareholders regarding recent company developments. As previously announced, Medifirst Solutions, Inc., received 510(k) clearance from the U.S. Food and Drug Administration ("FDA" to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Medifirst is pleased to announce that it has made substantial progress in setting up its infrastructure for sales and compliance. The Company has engaged MDI Consultants, a leading provider of quality assurance, regulatory compliance, FDA consulting and clinical services to the healthcare industry. MDI Consultants will be hands-on with assisting and overseeing the implementation of the Company's internal controls and procedures as mandated by the FDA. These controls and procedures will be implemented in the Company's sales office, as well as at its manufacturer's facility. Commented President Bruce J. Schoengood, "We are very pleased to continue our relationship with MDI Consultants, who played a crucial role in successfully getting the FDA clearance, as Medifirst enters into the sales phase of operations."
In preparing to ramp up and roll out its sales division, Medifirst is pleased to announce that it has leased new office space in which to run its sales and training functions and operations which will include all FDA mandated internal controls and procedures. Medifirst's new office space, located in Marlboro, New Jersey, will provide professional space for training and testing. It will also handle all administrative functions for the Laser Division.
The Company previously announced that it was aggressively putting together a sales & distribution team to offer its Time Machine Lasers in the US market. Continued CEO Schoengood, "We have come to terms with an experienced National Sales Director with established credentials in the medical device industry and upon the completion of contracts and agreements, the Company will release an official announcement which is anticipated in the upcoming days. Additionally, the company has come to terms with additional top industry advisors and announcements are forthcoming as agreements are completed."
Continued CEO Schoengood, "Medifirst has also made substantial progress for financing, inventory and manufacturing, as well as marketing and advertising. All components of building a national brand with national sales are being addressed. We will be releasing updates on these developments in the upcoming days and weeks. The Company appreciates the patience of its shareholders and supporters during this exciting time."
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA"
to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Medifirst Solutions, Inc
Investor Relations
(732) 786-8044
admin@medifirstsolutions.com
www.medifirstsolutions.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
MEDIFIRST SOLUTIONS ANNOUNCES SHAREHOLDER UPDATE
Sep 13, 2016
OTC Disclosure & News Service
Freehold, NJ - FOR IMMEDIATE RELEASE
Contact: Investor Relations
Phone: (732) 786-8044
Email: info@medifirstsolutions.com
Website: www.medifirstsolutions.com
Medifirst continues to ramp up for sales
Freehold, NJ – September 13, 2016 – MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “Company” or “Medifirst”) would like to update shareholders regarding recent company developments. As previously announced, Medifirst Solutions, Inc., received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device.
Medifirst is pleased to announce that it has made substantial progress in setting up its infrastructure for sales and compliance. The Company has engaged MDI Consultants, a leading provider of quality assurance, regulatory compliance, FDA consulting and clinical services to the healthcare industry. MDI Consultants will be hands-on with assisting and overseeing the implementation of the Company’s internal controls and procedures as mandated by the FDA. These controls and procedures will be implemented in the Company’s sales office, as well as at its manufacturer’s facility. Commented President Bruce J. Schoengood, “We are very pleased to continue our relationship with MDI Consultants, who played a crucial role in successfully getting the FDA clearance, as Medifirst enters into the sales phase of operations.”
In preparing to ramp up and roll out its sales division, Medifirst is pleased to announce that it has leased new office space in which to run its sales and training functions and operations which will include all FDA mandated internal controls and procedures. Medifirst’s new office space, located in Marlboro, New Jersey, will provide professional space for training and testing. It will also handle all administrative functions for the Laser Division.
The Company previously announced that it was aggressively putting together a sales & distribution team to offer its Time Machine Lasers in the US market. Continued CEO Schoengood, “We have come to terms with an experienced National Sales Director with established credentials in the medical device industry and upon the completion of contracts and agreements, the Company will release an official announcement which is anticipated in the upcoming days. Additionally, the company has come to terms with additional top industry advisors and announcements are forthcoming as agreements are completed.”
Continued CEO Schoengood, “Medifirst has also made substantial progress for financing, inventory and manufacturing, as well as marketing and advertising. All components of building a national brand with national sales are being addressed. We will be releasing updates on these developments in the upcoming days and weeks. The Company appreciates the patience of its shareholders and supporters during this exciting time.”
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
# # #
Forward-Looking Statements:
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Copyright © 2016 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
(0)
(0)Scroll down for more posts ▼